Clinical Trial Update: A Study of TAK-164 in Participants With Advanced Gastrointestinal (GI) Cancer Expressing Guanylyl Cyclase C (GCC) [Phase 1]

View source ↗

Summary

Phase 1 trial of TAK-164 in advanced GI cancers expressing GCC was terminated; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colon Cancer
• Esophageal Cancer
• Gastrointestinal Malignancies
• Gastrointestinal Neoplasms
• Malignant Tumors of Digestive Organs
• Pancreatic Cancer
• Stomach Cancer

Drugs mentioned

• TAK-164

Snippet

Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: Gastrointestinal Neoplasms; Esophageal, Stomach, Pancreas, Colon Neoplasms; Malignant Tumors of Digestive Organ; Advanced Gastrointestinal Malignancies | Phase 1 | Status: TERMINATED | Results posted: 2021-03-22